The Asia-Pacific self-monitoring blood glucose devices market is expected to expand at a CAGR of 6.34% during the 2019-2024 period, owing to technological breakthroughs, rising obesity, and the increasing prevalence of diabetes.
Product Segment Insights:
The testing strips segment is expected to hold the highest market share (81.64%) in 2019. Owing to the development of innovative testing strips, and a massive increase in the incidence of diabetes, this segment is expected to witness a high CAGR of 6.94% during the forecast period. The glucometers segment is expected to remain steady while generating 12% of the revenue in the Asia-Pacific market in 2019. Factors like the advantages of glucometers over regular monitoring methodologies and the production of a wide range of devices will drive this segment. However, variations in results due to external and physiological factors will lead to a comparatively low CAGR (4.95%) during the 2019-2024 period.
End User Segment Insights:
The shift of medical services to decentralized surroundings like patients’ homes and the development of portable and user-friendly blood glucose monitoring devices will enable the home settings segment to expand at a CAGR of 6.82% during the 2019-2024 period. The hospitals sector will generate almost 7% of the total market revenue by 2019, and is anticipated to expand at a CAGR of 4.78% during the forecast period.
China and India account for half of the total diabetic population in the Asia-Pacific region. Advanced medical facilities, awareness programs, and cost-effective treatments to tackle diabetes will transform this region into the fastest-growing SMBG devices market in the world. China is expected to expand at a CAGR of 6.62% during the forecast period, while healthcare initiatives and government programs in India will enable the market in the country to expand at a CAGR of 6.46%.
• Roche Holding
• Abbott Laboratories
• Terumo Medical